scholarly journals Low Adherence Achieves High HCV Cure Rates Among People Who Inject Drugs Treated With Direct-Acting Antiviral Agents

2020 ◽  
Vol 7 (10) ◽  
Author(s):  
Brianna L Norton ◽  
Matthew J Akiyama ◽  
Linda Agyemang ◽  
Moonseong Heo ◽  
Irene- Pericot-Valverde ◽  
...  
Keyword(s):  
Hepatitis C ◽  
People Who Inject Drugs ◽  
Antiviral Agents ◽  
Virologic Response ◽  
Direct Acting Antiviral ◽  
Suboptimal Adherence ◽  
Direct Acting ◽  
Cure Rates ◽  
Methadone Program ◽  
Direct Acting Antiviral Agents

Abstract We measured hepatitis C virus (HCV) adherence via electronic blister packs for 145 people who inject drugs treated on-site in a methadone program. The overall sustained virologic response (SVR) rate was 96% (95% CI, 91%–98%), and overall daily adherence was 78% (95% CI, 76%–81%). Participants who achieved at least 50% adherence had an overall SVR rate of 99%, with each 5% adherence interval >50% achieving at least 90% adherence. Suboptimal adherence may still lead to cure in the direct-acting antiviral era.

scholarly journals Sustained Viral Response in a Hepatitis C Virus-Infected Chimpanzee via a Combination of Direct-Acting Antiviral Agents

2010 ◽  
Vol 55 (2) ◽  
pp. 937-939 ◽  
Author(s):  
David B. Olsen ◽  
Mary-Ellen Davies ◽  
Larry Handt ◽  
Kenneth Koeplinger ◽  
Nanyan Rena Zhang ◽  
...  
Keyword(s):  
Hepatitis C ◽  
Antiviral Agents ◽  
Sustained Viral Response ◽  
Virologic Response ◽  
Proof Of Concept ◽  
Viral Response ◽  
Direct Acting Antiviral ◽  
Infected Chimpanzee ◽  
Direct Acting ◽  
Direct Acting Antiviral Agents

ABSTRACTEfforts to develop novel, interferon-sparing therapies for treatment of chronic hepatitis C (HCV) infection are contingent on the ability of combination therapies consisting of direct antiviral inhibitors to achieve a sustained virologic response. This work demonstrates a proof of concept that coadministration of the nucleoside analogue MK-0608 with the protease inhibitor MK-7009, both of which produced robust viral load declines as monotherapy, to an HCV-infected chimpanzee can achieve a cure of infection.

scholarly journals Sustained Virologic Response for Chronic Hepatitis C Infection After 27 Days of Treatment with Sofosbuvir and Ribavirin

2014 ◽  
Vol 1 (1) ◽  
Author(s):  
Eric G. Meissner ◽  
Amy Nelson ◽  
Miriam Marti ◽  
Henry Masur ◽  
Anu Osinusi ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
Sustained Virologic Response ◽  
Antiviral Agents ◽  
Virologic Response ◽  
Hepatitis C Infection ◽  
Direct Acting Antiviral ◽  
Direct Acting ◽  
Direct Acting Antiviral Agents

Abstract Successful treatment of chronic hepatitis C virus infection can now be achieved using direct-acting antiviral agents without interferon. In this report, we present a patient who achieved a sustained virologic response after 27 days of treatment with sofosbuvir and ribavirin. It is imperative to identify factors that allow for shorter treatment times in some individuals.

Detection of Occult Hepatitis C Virus Infection in Patients Who Achieved a Sustained Virologic Response to Direct-Acting Antiviral Agents

QJM ◽  
2021 ◽  
Vol 114 (Supplement_1) ◽  
Author(s):  
Tarek Mohamed Yousef ◽  
Maha Mohsen Mohamed Kamal El Din ◽  
Tari Magdy Aziz George ◽  
Amr Adel Elzohary Mohamed
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Antiviral Agents ◽  
Virologic Response ◽  
Hcv Rna ◽  
Occult Hepatitis ◽  
Direct Acting Antiviral ◽  
Direct Acting ◽  
Occult Hepatitis C ◽  
Direct Acting Antiviral Agents

Abstract Background Occult infection with hepatitis C virus (HCV) is defined as the presence of the HCV genome in either liver tissue or peripheral blood monocytes, despite constant negative results from tests for HCV RNA in serum. Objectives The aim of the study to detect the prevalence of occult hepatitis C Virus infection in patients who achieved a sustained virologic response (SVR) to direct-acting antiviral agents and to outline predictors of OCI. Patients and Methods This study included 100 patients with chronic HCV infection without liver cirrhosis attending to hepatitis C clinics at Ain Shams University Hospital, Ahmed Maher Teaching hospital and Elgomhorya Teaching Hospital.who received sofosbuvir (400mg) plus daclatasvir (60mg) daily for 12 weeks with or without ribavirin according to National committee to combat viral hepatitis (NCCVH) protocol. Results We tested peripheral blood for HCV RNA in PBMCs to detect OCI. Occult HCV was found positive in 12% of the studied cases. Occult HCV was positive more in male cases. Positive cases had significantly lower age, and higher total bilirubin, direct bilirubin, AST and ALT levels. Age had significant moderate diagnostic performance in predicting occult HCV, while direct bilirubin has significant low diagnostic performance in predicting occult HCV. Conclusion OCI following direct antiviral therapy may be present in some cases, and this may require further testing of patients with SVR particularly in younger male patients with persistantly high liver enzymes.

scholarly journals Postsustained Virological Response Management in Hepatitis C Patients

2020 ◽  
Vol 40 (03) ◽  
pp. 233-239 ◽  
Author(s):  
Chiara Masetti ◽  
Ana Lleo ◽  
Matteo Colombo ◽  
Massimo Colombo ◽  
Alessio Aghemo
Keyword(s):  
Liver Disease ◽  
Hepatitis C ◽  
Virological Response ◽  
Antiviral Agents ◽  
Direct Acting Antiviral ◽  
Clinically Significant ◽  
Complications Of Cirrhosis ◽  
Direct Acting ◽  
Cure Rates ◽  
Direct Acting Antiviral Agents

AbstractThe introduction of direct-acting antiviral agents (DAA) has revolutionized management and care of patients with chronic hepatitis C virus (HCV) infection, leading to cure rates higher than 90% in patients with advanced liver disease as well. Viral eradication has been associated with longer survival, reduced mortality from both hepatic and extrahepatic causes, improvement in liver function, and reduced incidence of HCV-related extrahepatic diseases. While patients with mild fibrosis can safely be discharged after achievement of a sustained virological response, patients with advanced fibrosis and cirrhosis remain at risk of developing complications of liver disease, thus requiring regular and life-long surveillance. Major complications of cirrhosis that need to be monitored are hepatocellular carcinoma onset and development or progression of clinically significant portal hypertension.

Sign in / Sign up

Export Citation Format

Share Document